PT-141 (Bremelanotide)

PT-141 (Bremelanotide) is a synthetic peptide analog of alpha-MSH that activates melanocortin-4 receptors (MC4R) in the central nervous system. It is the first FDA-approved peptide treatment for hypoactive sexual desire disorder, acting through central nervous system pathways rather than vascular mechanisms.